Aspen Pharmacare

The Pharmaceutical Industry in South Africa 2023 - Profiles of 120+ Companies Including Aspen Pharmacare, Adcock Ingram, Bayer, GlaxoSmithKline, Pfizer, Clicks, Dis-Chem & Nativa - ResearchAndMarkets.com

Retrieved on: 
Monday, February 19, 2024
Health, Pharmaceutical, Click, National health insurance, Pfizer, Investment, Mineral, Growth, Pharmacy, Dis-Chem, Conditional sentence, Public sector, TB, Aspen Pharmacare, Malaria, Private sector, COVID-19, GSK plc, Research, Face, Pressure, Cancer, Pharmaceutical industry

The "Pharmaceutical Industry in South Africa 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmaceutical Industry in South Africa 2023" report has been added to ResearchAndMarkets.com's offering.
  • More than 80% of South African pharmaceutical manufacturing and distribution revenue is from the private sector.
  • The pharmaceutical industry is well developed and supported by strong R&D and advanced manufacturing capabilities, including biotechnology manufacturing facilities.
  • There are profiles of 128 companies including local dominant players Aspen Pharmacare and Adcock Ingram, multinationals such as Bayer, GlaxoSmithKline and Pfizer and retailers Clicks and Dis-Chem and other players such as Nativa.

Mallinckrodt Announces Board of Directors and Leadership Updates

Retrieved on: 
Friday, February 2, 2024
Public, Genetics, Eli Lilly and Company, ExxonMobil, CFO, Eli Lilly, Patient, Teva Pharmaceuticals, Marketing, Executive Committee, Barr Pharmaceuticals, Sigi, Ecology, Morgan Stanley, Amneal Pharmaceuticals, Aspen Pharmacare, ViiV Healthcare, Employment, Bausch Health, GSK plc, The Company, Thermo Fisher Scientific, Therapy, Chairperson, KKR, Engineering, Management

DUBLIN, Feb. 2, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced the appointments of Paul Bisaro, Katina Dorton, Abbas Hussain and Wesley Wheeler to its Board of Directors, effective immediately. Mr. Bisaro has also been reappointed to his previous role as Board Chair. In addition, the Company announced that Siggi Olafsson has entered into a new employment agreement and will continue in his roles as Mallinckrodt's President and Chief Executive Officer and a member of the Board.

Key Points: 
  • Four Directors Added to Board Bring Seasoned Experience in Pharmaceuticals, Healthcare, Finance and Operations
    Siggi Olafsson Will Continue as President, CEO and Board Member
    DUBLIN, Feb. 2, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced the appointments of Paul Bisaro, Katina Dorton, Abbas Hussain and Wesley Wheeler to its Board of Directors, effective immediately.
  • Our ability to attract these accomplished directors is a testament to what we have achieved so far and the opportunities ahead for Mallinckrodt."
  • Select professional highlights of Mallinckrodt's new directors include:
    Paul Bisaro is a healthcare industry leader with more than three decades of leadership experience at generic and branded pharmaceutical companies.
  • With the appointment of Messrs Bisaro, Hussain and Wheeler and Ms. Dorton, Mallinckrodt's Board comprises seven directors.

Insights on the Local Anesthesia Drugs Global Market to 2027 - by Drug Type, Mode of Administration, Distribution Channel and Region

Retrieved on: 
Saturday, January 28, 2023
Septodont, Injection, Gastritis, Esophagitis, Dental care, Mouth, Sore throat, Endo International, Biting, Tropical ulcer, COVID-19, Consciousness, Hernia, Sympathetic nervous system, Baxter International, Anesthesia, Prevalence, Nerve, MI, Ropivacaine, Pfizer, Ulcer, Heartburn, Aspen Pharmacare, Semiconductor, Dentistry, Drug, Pharmaceutical industry, Potash, Distribution (marketing), Growth, Levobupivacaine

The global local anesthesia drugs market size reached US$ 2.77 Billion in 2021.

Key Points: 
  • The global local anesthesia drugs market size reached US$ 2.77 Billion in 2021.
  • Local anesthesia drugs are chemical compounds producing anesthesia by inhibiting the excitation of nerve endings or blocking conduction in peripheral nerves.
  • What has been the impact of COVID-19 on the global local anesthesia drugs market?
  • What is the structure of the global local anesthesia drugs market and who are the key players?

DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA

Retrieved on: 
Tuesday, February 1, 2022
Growth, Safety, Patient, Gonadotropin, Infection, Debiopharm, Prostate cancer, Aspen Pharmacare, Paradies, Commercial, New product development, Group, Man, Partnership, Disease, Health, Gonadotropin-releasing hormone, Geography, Business development, Aspen, Quality of life, Testosterone, Pharmaceutical industry, African, Triptorelin

LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022 /PRNewswire/ -- Debiopharm( www.debiopharm.com ), a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational pharmaceutical company announced today their partnership to launch Trelstar(Triptorelin) in South Africa for the treatment of locally advanced and metastatic hormone dependent prostate cancer.

Key Points: 
  • LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022 /PRNewswire/ -- Debiopharm( www.debiopharm.com ), a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational pharmaceutical company announced today their partnership to launch Trelstar(Triptorelin) in South Africa for the treatment of locally advanced and metastatic hormone dependent prostate cancer.
  • (Trelstar, a synthetic analogue of GnRH (Gonadotropin Releasing Hormone) developed by Debiopharm, will be marketed by Aspen in South Africa.
  • Deprivation of testosterone stops the growth of hormone dependent prostate cancer, alleviating pain and improving the quality of life of patients.
  • Aspen Pharmacare is excited to be able to deliver a world class oncology product in the treatment of prostate cancer and we are privileged to partner with Debiopharm to commercialize Trelstarwithin the South African market.

DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA

Retrieved on: 
Tuesday, February 1, 2022
Growth, Safety, Patient, Gonadotropin, Infection, Debiopharm, Prostate cancer, Aspen Pharmacare, Paradies, Commercial, New product development, Group, Man, Partnership, Disease, Health, Gonadotropin-releasing hormone, Geography, Business development, Aspen, Quality of life, Testosterone, Pharmaceutical industry, African, Triptorelin

LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022 /PRNewswire/ -- Debiopharm( www.debiopharm.com ), a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational pharmaceutical company announced today their partnership to launch Trelstar(Triptorelin) in South Africa for the treatment of locally advanced and metastatic hormone dependent prostate cancer.

Key Points: 
  • LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022 /PRNewswire/ -- Debiopharm( www.debiopharm.com ), a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational pharmaceutical company announced today their partnership to launch Trelstar(Triptorelin) in South Africa for the treatment of locally advanced and metastatic hormone dependent prostate cancer.
  • (Trelstar, a synthetic analogue of GnRH (Gonadotropin Releasing Hormone) developed by Debiopharm, will be marketed by Aspen in South Africa.
  • Deprivation of testosterone stops the growth of hormone dependent prostate cancer, alleviating pain and improving the quality of life of patients.
  • Aspen Pharmacare is excited to be able to deliver a world class oncology product in the treatment of prostate cancer and we are privileged to partner with Debiopharm to commercialize Trelstarwithin the South African market.

Productivity Without Borders Possible With Xerox® Workflow Central

Retrieved on: 
Tuesday, November 2, 2021
Networks, Internet, Data Management, Technology, Software, Efficiency, Microsoft, Xerox, Microsoft Office, Translation, Knowledge, Word, Aspen Pharmacare, Azure, Video game console, Typesetting

Today Xerox announced the new Xerox Workflow Central , a secure, cloud-based software platform providing access to workflow automation and digitization tools, helping todays teams overcome everyday workflow challenges for unstoppable productivity, from any location, at any time.

Key Points: 
  • Today Xerox announced the new Xerox Workflow Central , a secure, cloud-based software platform providing access to workflow automation and digitization tools, helping todays teams overcome everyday workflow challenges for unstoppable productivity, from any location, at any time.
  • Through Xeroxs award winning ConnectKey technology, Xerox Workflow Central makes it easy to transform documents seamlessly from any PC, tablet, mobile device or multifunction printer.
  • Work and working styles are continually being redefined, so we designed Xerox Workflow Central with ease of use as a top priority.
  • Xerox Workflow Central is available at various levels through a straightforward subscription model that comes with unlimited users and devices.

Acino acquires selected Aspen brands in South Africa

Retrieved on: 
Friday, October 22, 2021
Nordic Capital, Aspen Pharmacare, Aspen, Region, Avista Capital Partners, Group, Certification, Partnership, BBBEE, Patient, Erectile dysfunction, Thrombosis, CEO, Gastroenterology, Health, Acquisition, GLOBE, Degenerative disease, Pharmaceutical industry

The acquisition will further strengthen Acinos footprint in South Africa by expanding their offering in these important therapeutic segments.

Key Points: 
  • The acquisition will further strengthen Acinos footprint in South Africa by expanding their offering in these important therapeutic segments.
  • John Norman, Regional Director English-Speaking Africa at Acino said, I am very pleased to sign this agreement with Aspen.
  • The acquisition of these trusted brands in South Africa represents excellent scaling and commercial opportunities for Acino as it expands its footprint in South Africa by adding these products to its existing product portfolio.
  • For more information: www.acino.swiss
    Headquartered in Durban, South Africa, Aspen is a leading global specialty and branded multinational pharmaceutical company in both emerging and developed markets.

Global $27.73 Bn Analgesics Markets, 2021-2026 by Drug Type, Drug Class, Pain Type, Route of Administration, Distribution Channel, Application, Competitive Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 2, 2021
Health, Pharmaceutical, USD, OTC, Policy, Arthritis, Opioid, Awareness, Trauma, GlaxoSmithKline, Government, AbbVie, Pains, Risk, Administration, AstraZeneca, Geography, Aspen Pharmacare, NSAID, Cancer, Chronic pain, Migraine, Application, Market share, FDA, CAGR, Abbott Laboratories, Analgesic, Degenerative disease, Route of administration, Research, Pharmacy, Sexual abuse, Growth, Peripheral neuropathy, GSK, Drug class, Pharmaceutical industry, Dietary supplement

Furthermore, advancements in treatment choices and the availability of well-established healthcare facilities are propelling the analgesics market demand.

Key Points: 
  • Furthermore, advancements in treatment choices and the availability of well-established healthcare facilities are propelling the analgesics market demand.
  • However, uncontrolled opioid prescriptions, drug misuse, and strict regulation and policy by the government restrain the market and create challenges for the global analgesics market growth.
  • Amongst all, the prescription segment is estimated to hold the highest market share during the forecast period.
  • Amongst all, the internal analgesics segment is estimated to hold the highest market share during the forecast period.